Mithra Recognized by the Scientific Community: the Contraception Journal Publishes a Scientific Article About E4 (Estetrol) FIESTA Phase II Study

  • Mithra Pharmaceuticals announces today the publication of a scientific article based on the results of the E4 FIESTA Phase II study of its estetrol-based product candidate Estelle®, a combined oral contraceptive composed of 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP).
  • The article describes the bleeding pattern and cycle control observed with different E4 combinations.
  • The published results are very interesting for the scientific community as they demonstrate the good bleeding profile of the Estetrol-based product candidate Estelle®, which will be confirmed in the coming phase 3 studies.

Liège, Belgium, 4 May 2016 – Mithra Pharmaceuticals announces today that an article has been published in the peer-reviewed Contraception Journal. The published results of the E4 FIESTA Phase II study are particularly encouraging for the imminent launch of the Phase III studies.

Read the Press Release